Health Care · Industrial Organic Chemicals

CDXS CODEXIS, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 1200375127 filings
Russell 2000

CDXS at a glance

CODEXIS, INC. (CDXS, SEC CIK 1200375) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), CODEXIS, INC. (CDXS) reported revenue of $70.4 million (up 18.6% from FY2024) and a net loss of $44.0 million. Diluted EPS was -$0.50.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding CODEXIS, INC. (CDXS) shares worth $45.3 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by MOORE ALISON on November 16, 2026 of 10,651 shares at $1.14 per share.
  • In the last 90 days, CDXS insiders reported 0 open-market purchases ($0) and 4 open-market sales ($31K) on Form 4, a net sale of $31K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$70.4M
+18.6% vs prior year
Insiders · 90 days
0 buys · 4 sells
Net −$31K
13F holders
26 funds
$45.3M · +0 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $19.3M, up $10.7M YoY from $8.6M
  • Product revenue $15.7M, up $8.9M, driven by $8.4M higher commercial pharmaceutical enzyme sales
  • Product gross margin 74% vs 64% YoY, reflecting a shift toward more profitable products
  • Operating loss $7.4M vs $18.9M YoY, net loss $8.1M vs $19.6M
  • Cash $29.2M vs $50.8M, operating cash use $30.6M, July equity offering net proceeds $24.9M

Risk Factors

  • Newly highlighted compliance risk: U.S. BIOSECURE Act enacted December 2025 could restrict counterparties deemed biotechnology companies of concern
  • Most material operational update: ECO GMP Manufacturing Center retrofit begins Q4 2026, with potential permitting delays and cost overruns
  • Regulatory risk: FDA could reject the Company’s FDCA exemption, requiring cGMP compliance and potentially halting product distribution
  • Market risk: customers contributed 48% of nine-month revenue, increasing exposure to customer losses or reduced purchases
  • Financial risk: Trinity LSA includes $7.5 million available through December 15, 2027 and liquidity covenant tied to $400.0 million market capitalization

AI summary of the CDXS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Codexis announced financial results for the quarter ended September 30, 2026
  • Full results and management commentary are contained in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $19.3M vs $8.6M, driven by higher-margin product launches at customer companies
  • Product gross margin 74.5% vs 64%, signaling improved mix and stronger near-term profitability
Filed Nov 10, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • $42.5M funded term loan, with up to $60.0M total borrowing capacity across three tranches
  • Variable interest rate floor 10.50%, creating substantial financing expense through November 2030

Item 1.02: Termination of a Material Definitive Agreement

  • Innovatus Loan Agreement terminated after full repayment of approximately $43.6 million
  • Payoff funded by Tranche A Loan proceeds and cash on hand

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 points investors to the Loan and Security Agreement described under Item 1.01
  • The agreement creates a direct financial obligation for Codexis, with terms and amount requiring review of the referenced exhibit

Item 3.02: Unregistered Sales of Equity Securities

  • Lender Warrants issued to financing counterparties through private-placement exemptions under Section 4(a)(2) and Rule 506
  • Warrants and underlying common shares unregistered, limiting resale absent SEC registration or another exemption
Filed Aug 11, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $14.9M versus $15.3M, while product revenue rose to $13.2M from $7.4M
  • Product gross margin improved to 73% from 72%, reflecting stronger mix toward newer, higher-margin products

Item 2.02: Results of Operations and Financial Condition

  • Codexis announced financial results for the quarter ended June 30, 2026
  • Full results and management commentary are contained in Exhibit 99.1

AI summaries of CDXS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CDXS

Don't miss the next CDXS filing

  • Alerts as it files. A push when CDXS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CDXS, by share count.
  • Ask anything. An AI agent that reads every CDXS filing and answers with sources.

CDXS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
MOORE ALISONSellNov 16, 2026$1.14
De Vre RaymondSellNov 9, 2026$1.11
Erbez GeorgiaSellOct 12, 2026$1.36
MOORE ALISONSellOct 12, 2026$1.36
DILLY STEPHEN GEORGEAJun 17, 2026-
Smith David VAJun 17, 2026-
Collins CynthiaAJun 17, 2026-
De Vre RaymondAJun 17, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$59.3M$70.4M
Operating Income--$58.5M-$41.7M
Net Income-$76.2M-$65.3M-$44.0M
Op. Margin--98.6%-59.3%
Net Margin--110.0%-62.5%
Balance Sheet
Total Assets$136.6M$149.0M$147.8M
Equity-$66.9M$50.5M
ROE--97.5%-87.0%
Per Share
EPS$-1.12$-0.89$-0.50
Cash Flow
Operating CF--$49.4M-$19.4M
CapEx$4.4M$4.3M$4.5M

Source: XBRL data in CODEXIS, INC. (CDXS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CDXS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CDXS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$45.3M
Q2 202626$69.1M
Q1 202627$44.1M
Q4 202523$43.0M
Q3 202524$61.5M
Q2 202525$60.4M
Q1 202520$46.0M
Q4 202416$72.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 187 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CDXS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
8-KNov 12, 2026Analysis-
10-QNov 12, 2026Analysis
8-KNov 10, 2026Analysis-
4Nov 10, 2026--
4Oct 14, 2026--
4Oct 14, 2026--
10-QAug 11, 2026Analysis
8-KAug 11, 2026Analysis-
SC 13GJul 29, 2026-
8-KJul 27, 2026Analysis-
8-KJul 23, 2026Analysis-
8-KJun 22, 2026Analysis-
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 11, 2026--
10-QMay 7, 2026Analysis
8-KMay 7, 2026Analysis
8-KApr 14, 2026Analysis-

Related Health Care companies

All Health Care →

CDXS SEC filings: frequently asked questions

Are CDXS insiders buying or selling?

In the last 90 days, CODEXIS, INC. (CDXS) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $30,558 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CDXS stock?

As of September 30, 2026, the largest CODEXIS, INC. (CDXS) holders among the 13F filers tracked by SignalX were BlackRock ($11.6 million), Millennium Management ($6.6 million), Vanguard Capital Management LLC ($6.0 million), Ameriprise Financial ($4.2 million), D.E. Shaw & Co ($2.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CDXS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), CODEXIS, INC. (CDXS) reported revenue of $70.4 million (up 18.6% from FY2024) and a net loss of $44.0 million. Diluted EPS was -$0.50. The figures come from the XBRL data in the 10-K.

What did CDXS report in its latest 8-K?

CODEXIS, INC. (CDXS) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Codexis announced financial results for the quarter ended September 30, 2026.

What are the latest CDXS SEC filings?

CODEXIS, INC. (CDXS) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 18, 2026.

What is CDXS's SEC CIK number?

CODEXIS, INC. (CDXS)'s SEC Central Index Key (CIK) is 1200375. EDGAR lists every CDXS filing under that number.

Ask anything about CDXS

The research agent reads CDXS's filings, financials, insider trades and 13F holders, then answers with sources.